Company Filing History:
Years Active: 1997-2006
Title: Ranjan Mukherjee: Innovator in Biopharmaceuticals
Introduction
Ranjan Mukherjee, a prolific inventor based in San Diego, California, has made significant contributions to the field of biopharmaceuticals. With a total of eight patents to his name, his innovative work primarily focuses on human peroxisome proliferator activated receptors and RXR modulators, which hold great potential for therapeutic applications.
Latest Patents
Ranjan’s latest patents include a novel human peroxisome proliferator activated receptor, known as hPPARγ. This invention distinguishes itself by differing from the mouse variant in both nucleotide and amino acid sequences. The patent details the isolated, purified, enriched, or recombinant nucleic acids encoding hPPARγ polypeptides, vectors containing those nucleic acids, and methods for screening agonists and antagonists that target hPPARγ.
Another significant patent focuses on dimer-selective RXR modulator compounds that exhibit agonist, partial agonist, or antagonist activity within RXR homodimers and heterodimers. This invention not only outlines the pharmacological uses of these compounds but also includes pharmaceutical compositions for therapeutic applications.
Career Highlights
Ranjan Mukherjee is currently associated with Ligand Pharmaceuticals, Inc., a company known for its innovative solutions in drug development and therapeutic solutions. His work has greatly contributed to advancing the understanding of receptor biology, which is crucial for creating new treatment options for various diseases.
Collaborations
Throughout his career, Ranjan has collaborated with esteemed colleagues, including Richard Alan Heyman and Rosemary Cesario. These partnerships have facilitated the exchange of ideas and have significantly aided the progress of his groundbreaking work in the biopharmaceutical sector.
Conclusion
Ranjan Mukherjee stands out as a leading inventor in the realm of biopharmaceutical innovation. His contributions through patents focusing on hPPARγ and RXR modulators exemplify his commitment to advancing science and enhancing healthcare. Through his ongoing work with Ligand Pharmaceuticals, Ranjan continues to drive innovation that promises to impact therapeutic practices in the future.